Table 1.

MDS patient characteristics of the material used for in vitro experiments

Patient ID	WHO 2016	IPSS	Agerange	Sex	Karyotype	Tracking lesions
P01	MDS-MLD	low	60–65	m	46,XY[20]	TET2
P02	MDS-EB1	int-1	60–65	m	46,XY[20]	SF3B1
P03	MDS-MLD	int-2	70–75	m	46,XY[20]	Not detected
P04	MDS-EB1	int-2	60–65	m	46,XY, + 1.der(1;16)(q10;p10)[18/20]	RUNX1, IDH1, IDH2, SRSF2
P05	MDS-EB2	high	60–65	m	45,X, -Y [11]; 45,X,-Y,del(9)(q21q32) [5]; 45,X,-Y,del(9)(q13q34)[4]	KRAS
P06	MDS-EB2	int-2	40–45	f	45,XX,-7[15]	IDH2
P07	MDS-MLD	int-1	70–75	m	46,XY[20]	Not detected
P08	MDS-RS-MLD	low	70–75	m	46,XY[20]	SF3B1
P09	MDS-MLD	int-1	80–85	m	46,XY[20]	Not detected
P10	MDS-MLD	int-1	80–85	f	46, XX[25]	ASXL1, DNMT3A
P11	MDS-EB1	int-1	55–60	f	46,XX[20]	TP53, SF3B1
P04_2	MDS-EB1	int-2	60–65	m	46,XY, + 1.der(1;16)(q10;p10)[18/20]	RUNX1, IDH1, IDH2, SRSF2

The table displays the WHO classification 2016, IPSS, age, sex and karyotype of the MDS patients whose MSCs were used for experiments

MDS Myelodysplastic Neoplasms, IPSS MDS risk score according to international prognostic scoring system, int Intermediate, m Male, f Female